Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis

Tumor necrosis factor inhibitor (TNFi) has been applied in the treatment of ankylosing spondylitis (AS) for many years but still with an unmed need due to inefficacy or intolerance. Current treatment guideline recommended the use of IL-17 inhibitors over a second TNFi in patients with primary nonres...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jin-Xian, Zhang, Li-Jun, Wei, James Cheng-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524761/
https://www.ncbi.nlm.nih.gov/pubmed/36465082
http://dx.doi.org/10.2478/rir-2020-0004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524761/
https://www.ncbi.nlm.nih.gov/pubmed/36465082
http://dx.doi.org/10.2478/rir-2020-0004

Ejemplares similares